Richard K Plemper

List of Publications by Year
in descending order

94 papers	4,396 citations	81839 39 h-index	123376 61 g-index
103 all docs	103 docs citations	103 times ranked	4666 citing authors

#	Article	IF	Citations
1	Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nature Microbiology, 2021, 6, 11-18.	5.9	323
2	Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine, 2019, 11, .	5.8	253
3	Tunable and reversible drug control of protein production via a self-excising degron. Nature Chemical Biology, 2015, 11, 713-720.	3.9	180
4	Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	162
5	A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology, 2012, 434, 129-136.	1.1	120
6	Single-Chain Antibody Displayed on a Recombinant Measles Virus Confers Entry through the Tumor-Associated Carcinoembryonic Antigen. Journal of Virology, 2001, 75, 2087-2096.	1.5	119
7	Promotion of virus assembly and organization by the measles virus matrix protein. Nature Communications, 2018, 9, 1736.	5.8	114
8	Strength of Envelope Protein Interaction Modulates Cytopathicity of Measles Virus. Journal of Virology, 2002, 76, 5051-5061.	1.5	111
9	Segmented Filamentous Bacteria Prevent and Cure Rotavirus Infection. Cell, 2019, 179, 644-658.e13.	13.5	106
10	Measles Virus Envelope Glycoproteins Hetero-oligomerize in the Endoplasmic Reticulum. Journal of Biological Chemistry, 2001, 276, 44239-44246.	1.6	97
11	Cell entry of enveloped viruses. Current Opinion in Virology, 2011, 1, 92-100.	2.6	94
12	Functional Interaction between Paramyxovirus Fusion and Attachment Proteins. Journal of Biological Chemistry, 2008, 283, 16561-16572.	1.6	93
13	Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Translational Research, 2020, 218, 16-28.	2.2	90
14	Systematic Approaches towards the Development of Host-Directed Antiviral Therapeutics. International Journal of Molecular Sciences, 2011, 12, 4027-4052.	1.8	79
15	A target site for template-based design of measles virus entry inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5628-5633.	3.3	78
16	Probing the Spatial Organization of Measles Virus Fusion Complexes. Journal of Virology, 2009, 83, 10480-10493.	1.5	78
17	Structural and Mechanistic Studies of Measles Virus Illuminate Paramyxovirus Entry. PLoS Pathogens, 2011, 7, e1002058.	2.1	75
18	Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. Nature Communications, 2021, 12, 6415.	5.8	74

#	Article	IF	Citations
19	Structure and organization of paramyxovirus particles. Current Opinion in Virology, 2017, 24, 105-114.	2.6	67
20	Nonpeptide Inhibitors of Measles Virus Entry. Journal of Medicinal Chemistry, 2006, 49, 5080-5092.	2.9	65
21	Characterization of a Region of the Measles Virus Hemagglutinin Sufficient for Its Dimerization. Journal of Virology, 2000, 74, 6485-6493.	1.5	64
22	Structural Rearrangements of the Central Region of the Morbillivirus Attachment Protein Stalk Domain Trigger F Protein Refolding for Membrane Fusion. Journal of Biological Chemistry, 2012, 287, 16324-16334.	1.6	63
23	Triggering the measles virus membrane fusion machinery. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3018-27.	3.3	63
24	A Stabilized Headless Measles Virus Attachment Protein Stalk Efficiently Triggers Membrane Fusion. Journal of Virology, 2013, 87, 11693-11703.	1.5	62
25	Polymerases of paramyxoviruses and pneumoviruses. Virus Research, 2017, 234, 87-102.	1.1	59
26	4â€²-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science, 2022, 375, 161-167.	6.0	58
27	Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluation. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5199-5203.	1.0	54
28	Mechanism for Active Membrane Fusion Triggering by Morbillivirus Attachment Protein. Journal of Virology, 2013, 87, 314-326.	1.5	54
29	Mutations in the Putative HR-C Region of the Measles Virus F 2 Glycoprotein Modulate Syncytium Formation. Journal of Virology, 2003, 77, 4181-4190.	1.5	52
30	Design of a Small-Molecule Entry Inhibitor with Activity against Primary Measles Virus Strains. Antimicrobial Agents and Chemotherapy, 2005, 49, 3755-3761.	1.4	52
31	Blue Native PAGE and Biomolecular Complementation Reveal a Tetrameric or Higher-Order Oligomer Organization of the Physiological Measles Virus Attachment Protein H. Journal of Virology, 2010, 84, 12174-12184.	1.5	52
32	An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model. Science Translational Medicine, 2014, 6, 232ra52.	5.8	52
33	Two Domains That Control Prefusion Stability and Transport Competence of the Measles Virus Fusion Protein. Journal of Virology, 2006, 80, 1524-1536.	1.5	48
34	Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity. Antimicrobial Agents and Chemotherapy, 2007, 51, 2293-2303.	1.4	48
35	Independent Structural Domains in Paramyxovirus Polymerase Protein. Journal of Biological Chemistry, 2012, 287, 6878-6891.	1.6	47
36	Functional and Structural Characterization of Neutralizing Epitopes of Measles Virus Hemagglutinin Protein. Journal of Virology, 2013, 87, 666-675.	1.5	45

#	Article	IF	Citations
37	Identification of Residues in the Human Respiratory Syncytial Virus Fusion Protein That Modulate Fusion Activity and Pathogenesis. Journal of Virology, 2015, 89, 512-522.	1.5	44
38	Next-generation direct-acting influenza therapeutics. Translational Research, 2020, 220, 33-42.	2.2	43
39	Structural Features of Paramyxovirus F Protein Required for Fusion Initiationâ€. Biochemistry, 2003, 42, 6645-6655.	1.2	42
40	The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics. Frontiers in Microbiology, 2015, 6, 459.	1.5	40
41	A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness. PLoS Computational Biology, 2020, 16, e1008451.	1.5	40
42	Non-nucleoside Inhibitors of the Measles Virus RNA-Dependent RNA Polymerase: Synthesis, Structureâ€"Activity Relationships, and Pharmacokinetics. Journal of Medicinal Chemistry, 2012, 55, 4220-4230.	2.9	39
43	Potent Host-Directed Small-Molecule Inhibitors of Myxovirus RNA-Dependent RNA-Polymerases. PLoS ONE, 2011, 6, e20069.	1.1	39
44	Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens. Biochemistry, 2015, 54, 5589-5604.	1.2	38
45	Potent Non-Nucleoside Inhibitors of the Measles Virus RNA-Dependent RNA Polymerase Complex. Journal of Medicinal Chemistry, 2008, 51, 3731-3741.	2.9	36
46	Molecular Determinants Defining the Triggering Range of Prefusion F Complexes of Canine Distemper Virus. Journal of Virology, 2014, 88, 2951-2966.	1.5	36
47	Sequential Conformational Changes in the Morbillivirus Attachment Protein Initiate the Membrane Fusion Process. PLoS Pathogens, 2015, 11, e1004880.	2.1	35
48	The Measles Virus Nucleocapsid Protein Tail Domain Is Dispensable for Viral Polymerase Recruitment and Activity. Journal of Biological Chemistry, 2013, 288, 29943-29953.	1.6	34
49	Reversible Inhibition of the Fusion Activity of Measles Virus F Protein by an Engineered Intersubunit Disulfide Bridge. Journal of Virology, 2007, 81, 8821-8826.	1.5	31
50	Target Analysis of the Experimental Measles Therapeutic AS-136A. Antimicrobial Agents and Chemotherapy, 2009, 53, 3860-3870.	1.4	31
51	The structurally disordered paramyxovirus nucleocapsid protein tail domain is a regulator of the mRNA transcription gradient. Science Advances, 2017, 3, e1602350.	4.7	29
52	Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. Current Opinion in Virology, 2019, 35, 1-13.	2.6	28
53	Measles Virus Glycoprotein Complexes Preassemble Intracellularly and Relax during Transport to the Cell Surface in Preparation for Fusion. Journal of Virology, 2015, 89, 1230-1241.	1.5	25
54	Identification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput Screening. Journal of Virology, 2016, 90, 7368-7387.	1.5	25

#	Article	IF	Citations
55	Progress and pitfalls of a year of drug repurposing screens against COVID-19. Current Opinion in Virology, 2021, 49, 183-193.	2.6	25
56	Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	25
57	Optimization of Potent and Selective Quinazolinediones: Inhibitors of Respiratory Syncytial Virus That Block RNA-Dependent RNA-Polymerase Complex Activity. Journal of Medicinal Chemistry, 2014, 57, 10314-10328.	2.9	23
58	The Unstructured Paramyxovirus Nucleocapsid Protein Tail Domain Modulates Viral Pathogenesis through Regulation of Transcriptase Activity. Journal of Virology, 2018, 92, .	1.5	23
59	Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex. Journal of Biological Chemistry, 2018, 293, 16761-16777.	1.6	23
60	Measles Virus Entry Inhibitors: A Structural Proposal for Mechanism of Action and the Development of Resistance. Biochemistry, 2008, 47, 13573-13583.	1.2	22
61	Structure-guided design of small-molecule therapeutics against RSV disease. Expert Opinion on Drug Discovery, 2016, 11, 543-556.	2.5	20
62	Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy- <scp>d</scp> -Phe- <scp>l</scp> -Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide. Journal of Virology, 2017, 91, .	1.5	20
63	Measles Resurgence and Drug Development. Current Opinion in Virology, 2020, 41, 8-17.	2.6	20
64	Measles control--can measles virus inhibitors make a difference?. Current Opinion in Investigational Drugs, 2009, 10, 811-20.	2.3	20
65	Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase. Nature Microbiology, 2020, 5, 1232-1246.	5.9	18
66	Dual Myxovirus Screen Identifies a Small-Molecule Agonist of the Host Antiviral Response. Journal of Virology, 2013, 87, 11076-11087.	1.5	17
67	Synergizing vaccinations with therapeutics for measles eradication. Expert Opinion on Drug Discovery, 2014, 9, 201-214.	2.5	17
68	Capturing Enveloped Viruses on Affinity Grids for Downstream Cryo-Electron Microscopy Applications. Microscopy and Microanalysis, 2014, 20, 164-174.	0.2	17
69	Host-Directed Inhibitors of Myxoviruses: Synthesis and in Vitro Biochemical Evaluation. ACS Medicinal Chemistry Letters, 2011, 2, 798-803.	1.3	15
70	Organization, Function, and Therapeutic Targeting of the Morbillivirus RNA-Dependent RNA Polymerase Complex. Viruses, 2016, 8, 251.	1.5	15
71	Bipartite interface of the measles virus phosphoprotein X domain with the large polymerase protein regulates viral polymerase dynamics. PLoS Pathogens, 2019, 15, e1007995.	2.1	15
72	Therapeutic targeting of measles virus polymerase with ERDRP-0519 suppresses all RNA synthesis activity. PLoS Pathogens, 2021, 17, e1009371.	2.1	13

#	Article	IF	Citations
73	A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern <i>In Vitro</i> and <i>In Vivo</i>. Journal of Virology, 2021, 95, e0112621.	1.5	13
74	Canine Distemper Virus Envelope Protein Interactions Modulated by Hydrophobic Residues in the Fusion Protein Globular Head. Journal of Virology, 2015, 89, 1445-1451.	1.5	12
75	Structural Insight into Paramyxovirus and Pneumovirus Entry Inhibition. Viruses, 2020, 12, 342.	1.5	12
76	Primary resistance mechanism of the canine distemper virus fusion protein against a small-molecule membrane fusion inhibitor. Virus Research, 2019, 259, 28-37.	1.1	10
77	Identification of Non-Nucleoside Inhibitors of the Respiratory Syncytial Virus Polymerase Complex. Journal of Medicinal Chemistry, 2017, 60, 2305-2325.	2.9	9
78	Biology must develop herd immunity against bad-actor molecules. PLoS Pathogens, 2018, 14, e1007038.	2.1	9
79	Viral evolution identifies a regulatory interface between paramyxovirus polymerase complex and nucleocapsid that controls replication dynamics. Science Advances, 2020, 6, eaaz1590.	4.7	9
80	Blocking Respiratory Syncytial Virus Entry: A Story with Twists. DNA and Cell Biology, 2015, 34, 505-510.	0.9	6
81	Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding. Nature Communications, 2021, 12, 5233.	5.8	6
82	Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase. Science Advances, 2022, 8, .	4.7	6
83	Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor. Journal of Virology, 2020, 94, .	1.5	5
84	Protein Degradation in Human Disease. Progress in Molecular and Subcellular Biology, 2002, 29, 61-84.	0.9	5
85	4â€²-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness. DNA and Cell Biology, 2022, 41, 699-704.	0.9	5
86	Editorial overview: Antiviral strategies: Antiviral drug development for single-stranded RNA viruses. Current Opinion in Virology, 2019, 35, iii-v.	2.6	2
87	The impact of high-resolution structural data on stemming the COVID-19 pandemic. Current Opinion in Virology, 2021, 49, 127-138.	2.6	2
88	4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science, 2021, , eabj5508.	6.0	2
89	Editorial overview: Special issue on antiviral strategies in Current Opinion in Virology. Current Opinion in Virology, 2021, 50, 95-96.	2.6	1
90	Targeting Measles Virus Entry. , 2003, , 321-336.		0

#	Article	IF	Citations
91	Title is missing!. , 2020, 16, e1008451.		0
92	Title is missing!. , 2020, 16, e1008451.		0
93	Title is missing!. , 2020, 16, e1008451.		0
94	Title is missing!. , 2020, 16, e1008451.		0